Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grant from Biogen.

The educational activity is jointly provided by:

Medical Crossfire®: Sequencing of Disease Modifying Therapies – Optimizing Outcomes in Patients with Multiple Sclerosis

Release Date: December 23, 2021
Expiration Date: December 23, 2022


Activity Overview

Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system characterized by demyelination and neurodegenerative progression. Most patients with MS experience relapses and remission of neurological symptoms, especially early in the disease course. Advances in understanding of the immune mechanisms that contribute to MS have led to the development of many disease-modifying therapies that target effector T cells, regulatory cells, B cells, and cell trafficking into the nervous system.
 
This online on-demand virtual webcast brings together renowned experts in MS. In this activity, 3 key thought leaders explore the latest data regarding current and emerging therapeutic strategies for the management of patients with MS. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with MS.
 
This educational activity is an archive of the live virtual webcast held on December 9, 2021.

Acknowledgement of Commercial Support:

This activity is supported by educational grant from Biogen.

The educational activity is jointly provided by:

company

 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward neurologists and MS subspecialists. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with MS will be invited to participate.
 

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review key clinical trial data for current and emerging therapies for the treatment of MS
  • Implement strategies to select optimal evidence-based treatments for patients in the early stages of MS
  • Formulate individualized treatment plans for patients with MS
  • Discuss approaches to shared decision-making to optimize patient adherence to the selected treatment plan

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 
 

Chair

Pasi A. Jänne, MD, PhD
Patricia K. Coyle, MD
Professor and Vice Chair of Clinical Affairs
Director MS Comprehensive Care Center
Department of Neurology
Stony Brook University Medical Center
Stony Brook, NY
 

Disclosures: Grant/Research Support: Actelion, Alkermes, Celgene, CorEvitas, Genentech/Roche, Genzyme/Sanofi, Janssen Pharmaceutical Companies of Johnson & Johnson, MedDay, National Institute of Neurological Disorders and Stroke, Novartis. Consultant: Accordant, Biogen, Bristol Myers Squibb, Celgene, Genzyme/Sanofi, GlaxoSmithKline, Horizon Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson, Mylan, Novartis, Viela Bio. Speaker's Bureau: Accordant, Biogen, Bristol Myers Squibb, Celgene, Genzyme/Sanofi, GlaxoSmithKline, Horizon Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson, Mylan, Novartis, Viela Bio.

Faculty

Mary Beth Beasley, MD
Joseph R. Berger, M.D
Professor of Neurology,
Associate Chief of MS Division
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
 

Disclosures: Grant/Research Support: Biogen and Genentech/Roche. Consultant: Celgene/Bristol Myers Squibb, Cellevolve, EMD Serono/Merck & Co, Genentech/Roche, Genzyme, Janssen/Johnson & Johnson, Morphic Therapeutic, NeuVIR, Novartis, Sanofi, Takeda, and TG Therapeutics. Other Support: Scientific Advisory or Data Safety Monitoring board for MAPI and Excision Bio Therapeutics.
 

Gregory Riely, MD
Clyde E. Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
 

Disclosures: Consultant: Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb, Celgene, Genentech/Roche, Genzyme/Sanofi, Merck & Co/EMD Serono, Novartis, Teva Pharmaceuticals.


PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.



Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By